Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM-101 in adults with birch pollen allergy
NCT04266028Phase 1Completed
- Sponsor
- Desentum
- Start
- Feb 2020
- Primary completion
- May 2021
- Modality
- Hydrogel Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DM-101 in birch pollen allergy (8 arms), sponsored by Desentum. Primary endpoint: Treatment Emergent Adverse Events. Started Feb 2020; status: completed.
02
Drugs
DM-101
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT04266028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04266028.